GENOME THERAPEUTICS CORP Form 8-K June 18, 2001

> CURRENT REPORT Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

MASSACHUSETTS 0-10824 04-2297484

(State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification Number)

> 100 BEAVER STREET WALTHAM, MASSACHUSETTS 02453

(Address, of principal executive offices, including zip code)

(781) 398-2300

(Registrant's Telephone number including area code)

PAGE 1 OF 4 PAGES.

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

On June 18, 2001, Genome Therapeutics Corp. issued a press release announcing that it has received milestone payments from Wyeth-Ayerst, the pharmaceutical division of American Home Products, for the completion of an advancement in a genomics-based alliance to develop novel therapeutics for the prevention and treatment of osteoporosis. Genome Therapeutics has received payments totaling \$5,000,000 as a result of the completion of the milestones. The milestone revenues are expected to be recognized in the 4th Quarter of the Company's Fiscal Year ended August 31, 2001. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ Stephen Cohen

Name: Stephen Cohen Title: Chief Financial Officer

Date: June 18, 2001

EXHIBIT INDEX

99.1 Press Release dated June 18, 2001